International Forum for RA Preliminary program

Transcription

1 International Forum for RA Preliminary program Saturday, September 23, :00 14:15 Welcome and introduction to the history of and purpose of IFRA Lars Klareskog, Zhanguo Li, Kazuhiko Yamamoto Session 1: The good aspects of the situation today and how we arrived here Chairs: Zhanguo Li, Kazuhiko Yamamoto 14:15 14:45 From ideas in research to clinical benefits. The long term perspectives Sir Ravinder Maini, Kennedy Institute, University of Oxford Session 2: The unresolved clinical and scientific problems of today and why are they unresolved? Chairs: Josef Smolen, Medical University of Vienna and Codruta Filip, PARE/EULAR 14:50 15:15 15:15 15:40 15:40 16:05 16:05 16:35 Patients needs and current scientific approaches to RA; Not always aligned. Johan Askling, Karolinska Institutet, Stockholm Clinical unresolved problem as seen from real life experience and registries Scientific unresolved problems in science Merete Hetland, Copenhagen University Chris Buckley, University of Birmingham Discussions on need for novel solutions to adess the most important unresolved questions Discussion led by chairpersons 16: Afternoon break with tea and coffe Session 3: Why do we get RA (1st part); What can we learn from genetic epidemiology and genomics? Chairs: Mike Brenner, Harvard Medical School and Anne Barton, The University of Manchester 17:00 17:25 17:25 17:50 17:50 18:15 18:15 18:30 Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis What can studies on environment and life style tell us? Kazuhiko Yamamoto, University of Tokyo Saedis Saevarsdottir, Karolinska Institutet, Stockholm Combining genetics and epigenetic data to define key pathogenic single cell populations in rheumatoid arthritis Soumya Raychadhuri, Harvard Medical School, Boston, MA Selected abstract: The association between HLA-DRB1 alleles and risk of rheumatoid arthritis is influenced by massive gene-gene interactions Lina-Marcela Diaz-Gallo, Karolinska Institutet, Stockholm

2 18:30 19:00 Discussions on strategic thinking concerning combinations of cohorts and biomarkers for future design of studies on pathogenesis, prevention and therapy Discussion introduced and led by chairpersons 19:00 > Reception at Aula Medica Sunday, September 24, 2017 Session 4: Why do we get RA? (2nd part) The longitudinal course of RA Chairs: Anna Rudin, Gothenburg University and Mike Holers, University of Colorado at Denver 8:30 8:55 8:55 9:20 9:20 9:45 9:45 10:20 From triggering to targeting; the longitudinal course of seropositive RA Anca Catrina, Karolinska Institutet, Stockholm Autoantibodies and their glycosylation during emergence of RA ACPAs, NETs and inflammation. New light on neutrophils Hans Ulrich Scherer, Leiden University Mariana Kaplan, NIH, Bethesda, MA Pathobiology of Rheumatoid Arthritis: Towards a Molecular Definition and Precision Medicine Cos Pitzalis, London 10:20 10:50 Morning break with coffee and fruits Session 5: Why do we get RA? (3rd part): Microbes and RA Chairs: Rene Toes, Leiden University Medical Center and Solbritt Rantapää- Dahlqvist, Umeå University 10:50 11:15 11:15 11:40 11:40 12:05 12:05 12:30 The bacterial way towards RA 1: The porphyromonas and PAD pathway Karin Lundberg, Karolinska Institutet, Stockholm The bacterial way towards RA 2: The Aggregatibacter and hypercitrullination way. Felipe Andrade, Johns Hopkins, Baltimore, MD Role of the microbiome in the pathogenesis of RA Xuan Zhang, Peking Union Medical College Discussions on strategies to understand the triggers and early stages of RA Discussion introduced and led by chairpersons from session 4 and 5 12:30 13:30 Lunch

3 Session 6: Adaptive vs. Innate immunity and mesenchymal functions as driving forces in RA Chairs: Andy Cope, King s College London and Steffen Gay, University of Zürich 13:30 13:55 Role of specific B and T cells immunity in the initiation of RA Vivianne Malmström, Karolinska Institutet, Stockholm 13:55 14:20 The B cell repertoire in RA Dan Mueller, University of Minnesota 14:20 14:45 14:45 15:00 15:00 15:15 15:15 15:30 Effects of monoclonal antibodies from RA patients on innate functions of synovial cells Bill Robinson, Stanford University, CA Selected abstract: Monoclonal ACPA-IgG feature extensive Fab glycosylation Katy Lloyd, Karolinska Institutet, Stockholm Selected abstract: The mutated RNA splicing protein hnrnp-a3 is a novel autoantigen in systemic rheumatic diseases a link to Warburg effect in RA Discussions on the driving forces of RA Blanka Marklein, Charite University, Berlin Discussion introduced and led by the chairpersons 15:30 16:00 Afternoon break with coffee Session 7: Adaptive vs innate immunity and mesenchymal functions in RA (continued) Chairs: Lisa van Baarsen, AMC and Guenter Steiner, Medical university of Vienna 16:00 16:25 16:25 16:50 16:50 17:15 17:15 17:40 17:40 17:55 MFAP5 plays a key role in invasion of FL-like synoviocyte in RA Genetics, T cell specificity and T cell regulation in RA Huji Xu, University of Queensland Jane Buckner, Benaroya Research Institute, Seattle, WA How can adaptive immune functions influence stromal cells in RA? Caroline Ospelt, University of Zürich How can we combine understanding of mesenchymal and immune functions in RA? Iain McInnes, University of Glasgow Selected abstract: Machine learning using rheumiatoid arthritis synovial gene expression data defines histologic features that correlate with systemic inflammation and autoantibodies Dana Orange, Rockefeller University 17:55 18:15 Discussion introduced and led by the chairpersons 18:15 19:30 Posters with poster competition, discussion clubs and other informal meetings with wine and cheese

4 Monday, September 25, 2017 Session 8: Genetics and function of citrullination and PAD and other post-translational modifications in RA Chairs: Caroline Grönwall, KI and Ger Pruijn, Radboud University Medical centre 8:30-8:45 8:45-9:10 9:10 9:35 9:35 9:50 Introduction to post-translational modifications The roles of PADs in RA Role of osteoclasts in bone inflammation Ger Pruijn, Radboud University Medical centre Hirofumi Shoda, University of Tokyo Hiroshi Takayanagi, University of Tokyo Selected abstract: RA-associated antibodies targeting post translational modification have different osteoclastogenesis potential Akilan Krishnamurthy, Karolinska Institutet, Stockholm 9:50 10:15 Discussions introduced and led by the chairpersons 10:15 10:40 Morning break with coffee Session 9: Can we prevent RA? Chairs: Dimitris Boupmas, Biomedical Research Foundation Academy Of Athens and Lars Alfredsson, KI 10:40-11:05 Trials for prevention: How to do it? Tom Huizinga, Leiden 11:05 11:30 11:30 11:55 11:55 12:20 How to understand and measure subjective symptoms that matter for the patient? Karim Raza, University of Birmingham Therapy is not only medicines. How to accomplish and measure effects of change of life style and environment? How can we prevent RA? Jill Norris, Denver Discussions introduced and led by the chairpersons 12:20 13:45 Lunch Session 10: Mechanisms of pain in RA Chairs: Christina Opava, KI and Alison Kent, PARE 13:45 14:10 14:10 14:35 Pain and cognition in RA, Which are the central mechanisms? Georg Schett, Erlangen University Clinic Longitudinal development of pain in RA Jon Lampa, Karolinska Institutet, Stockholm 14:35 15:00 Antibody-mediated pain Camilla Svensson, Karolinska Institutet, Stockholm

5 15:00 15:30 Afternoon break with coffee Session 11: New ways of understanding the individual s most urgent problems and how they change over time; What role for e-health Chairs: Gerd Burmester, Charité, Berlin and TBC 15:30 15:55 15:55 16:20 16:20 17:05 Emerging opportunities for digital health research in RA Will Dixon, University of Manchester Meeting the patients early with an app: What options and what obstacles? Sofia Ernestam, Karolinska Institutet What will happen with patient reported outcomes in the future? Tore Kvien, Oslo University 17:05 17:30 Discussion introduced and led by the chairpersons from session 10 and 11 18:30 Leave for City Hall (tentative) Tuesday, September 26, 2017 Session 12: Future trials for prevention and curative treatments; Which strategies? Chairs: Marc Feldmann, University of Oxford and Ronald van Vollenhoven, KI and University of Amsterdam 8:30 8:55 Tolerance therapies will they become real? Ranjeny Thomas, University of Queensland 8:55 9:20 9:20 9:45 Tolerizing T cells New smart trial designs Rikard Holmdahl, Karolinska Institutet John Isaacs, Newcastle University 9:45-10:15 Morning break with coffee 10:15 10:40 Bioelectronic Medicine: Technology Targeting Molecular Mechanisms for Therapy Peder Olofsson, Karolinska Institutet, Stockholm

6 Session 13: Future strategies for prevention and treatments of RA a collaboration between academia, industry and health care chairs: Lars Klareskog (KI), Marc Feldmann (University of Oxford) and Ronald van Vollenhoven (KI and University of Amsterdam) 10:45 12:15 Discussion with representatives from academia, industry and health care led by the chairpersons Perspectives from industry, academia and health care; How should we combine our efforts to make the new generation of curative and preventive therapies real? Confirmed guests: Anish Suri, Janssen, Aaron Winkler, Pfizer, Steven Nadler, BMS 12:15 12:40 Clinical and basic research of RA in China challenge and catch up Zhanguo Li, Beijing University 12:40 Lunch and Departures